Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is one the major limiting factor for the successful outcome of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), with a reported mortality rate of up to 50%. VOD/SOS is thought to result from an endothelial damage and occurs with a highly variable incidence ranging from 8% to 14%. Management of patients with VOD/SOS is based on both prevention and treatment, which rely on non-pharmacological approaches, for instance the control of additional risk factors, and pharmacologic treatments.
Herein we provide a review of the current understanding for the management of patients with VOD/SOS after allogeneic HSCT
